Novonesis (Novozymes) B
NSISBC
Rank in Stocks
#1160
Established in January 2024 through the amalgamation of Novozymes A/S and Chr.... Established in January 2024 through the amalgamation of Novozymes A/S and Chr. Hansen, Novonesis now stands as a prominent global leader in biosolutions. The firm's activities encompass the worldwide development and commercialization of industrial enzymes, diverse microorganisms, and vital biopharmaceutical ingredients. Distinctively, its Class B shares are listed independently and actively traded on various European exchanges.
Share Price
$70.10
Last synced: 2026-10-21
Market Cap
$19.48B
Change (1 day)
-4.64%
Change (1 year)
10.57%
Country
DK
Trade Novonesis (Novozymes) B (NSISBC)
Category
Basic Materials
P/B ratio for Novonesis (Novozymes) B (NSISBC)
P/B ratio as of 2026 TTM: 0
According to Novonesis (Novozymes) B latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Novonesis (Novozymes) B from 2026 to 2026
P/B ratio at the end of each year
| Year | P/B Ratio | Change |
|---|---|---|
| Not enough data for the provided dates. | ||
P/B ratio for similar companies or competitors
| Company | P/B Ratio | P/B Ratio Difference | Country |
|---|---|---|---|
| 5.8311 | - |
GB
|
|
| - | - |
FR
|
|
| 20.6105 | - |
US
|
|
| 8.0509 | - |
US
|
|
| 4.6944 | - |
US
|
